Currently Viewing:
Supplements Importance of Selecting the Appropriate Therapy for Inflammatory Bowel Disease in the Managed Care E

Report: Economic Implications of Inflammatory Bowel Disease and Its Management

Foram Mehta, MS, RPh
 


Author affiliation: Aetna Medicare, Old Bridge, NJ.
Funding source: This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Author disclosure: Ms Mehta has no relevant financial relationships with commercial interests to disclose.
Authorship information: Acquisition of data; analysis and interpre-tation of data; and critical revision of the manuscript for important intellectual content.
Address correspondence to: MehtaF@aetna.com.

1. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519-525. doi: 10.1007/s10620-012-2371-5.
2. The facts about inflammatory bowel diseases. Crohn’s & Colitis Foundation of America website. http://www.ccfa.org/assets/pdfs/updatedibdfactbook.pdf. Published November 2014. Accessed September 15, 2015.
3. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis prac-tice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501-523. doi: 10.1038/ajg.2009.727.
4. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104(2):465-483. doi: 10.1038/ajg.2008.168.
5. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel dis-eases. Gastroenterology. 2011;140(6):1785-1794. doi: 10.1053/j.gastro.2011.01.055.
6. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50(11):1261-1272. doi: 10.1097/JOM.0b013e318181b8ca.
7. Umanskiy K, Fichera A. Health related quality of life in inflam-matory bowel disease: the impact of surgical therapy. World J Gastroenterol. 2010;16(40):5024-5034.
8. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11(10):909-918.
9. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11(5):488-496.
10. Stone CD. The economic burden of inflammatory
bowel disease: clear problem, unclear solution. Dig Dis Sci. 2012;57(12):3042-3044. doi: 10.1007/s10620-012-2417-8.
11. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907-1913. doi: 10.1053/j.gastro.2008.09.012.
12. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003:98(5):1064-1072.
13. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016;111(1):15-23. doi: 10.1038/ajg.2015.207.
14. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179-1187. doi: 10.1053/j.gastro.2012.08.002.
15. Everhart JE. Inflammatory bowel disease. In: Everhart JE, ed. The Burden of Digestive Diseases in the United States. Washington, DC: US Government Printing Office; 2008:97-106.
16. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-754. doi: 10.1053/j.gastro.2009.01.015.
17. CDC/NCHS national hospital discharge survey: United States, 2010. CDC website. http://www.cdc.gov/nchs/nhcs.htm. Accessed January 21, 2016.
18. Cohen R, Skup M, Ozbay AB, et al. Direct and indirect health-care resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015;18(6):447-456. doi: 10.3111/13696998.2015.1021353.
19. Meek PD, Racz MJ, Kehoe JE, Cosler LE, Carter JA, Yen L. Direct and indirect cost burden of ulcerative colitis: a matched analysis of healthcare costs, absenteeism, and short term disability costs in U.S. patients with and without ulcerative colitis. Gastroenterol. 2013;144(5 [suppl 1]):S-765.
20. Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance sta-tus, income, and clinical care setting. PeerJ. 2014;2:e587. doi: 10.7717/peerj.587.
21. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17(7):1603-1609. doi: 10.1002/ibd.21488.
22. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24(2):319-328.
23. Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman M. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm. 2008;14(4):352-362.
24. Common practices in formulary management systems: a report prepared by the Academy of Managed Care Pharmacy. Academy of Managed Care Pharmacy website. http://www.amcp .org/WorkArea/DownloadAsset.aspx?id=9274. Published June 2000. Accessed January 14, 2015.
25. Porter ME. A strategy for health care reform--toward a value-based system. N Engl J Med. 2009;361(2):109-112. doi: 10.1056/NEJMp0904131.
26. Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law. 2008;33(2):225-247. doi: 10.1215/03616878-2007-054.
27. Physician Quality Reporting System. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/index. html?redirect=/pqri/. Updated December 23, 2015. Accessed January 21, 2016.
28. Melmed GY, Siegel CA. Quality improvement in inflammato-ry bowel disease. Gastroenterol Hepatol (N Y). 2013;9(5):286-292.
29. CCFA's Quality of Care Initiative. Crohn's & Colitis Foundation of America website. http://www.ccfa.org/science-and-professionals/programs-materials/qualityofcare.html. Accessed January 21, 2016.
30. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289-297. doi: 10.1038/ajg.2009.579.
31. Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn's dis-ease treated in a managed care environment. Inflamm Bowel Dis. 2008;14(12):1707-1714. doi: 10.1002/ibd.20530.
32. Hillson E, Dybicz S, Waters HC, et al. Health care expen-ditures in ulcerative colitis: the perspective of a self-insured employer. J Occup Environ Med. 2008;50(8):969-977. doi: 10.1097/JOM.0b013e31816fd663.
33. Mackowiak JI. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of bal-salazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface. 2006;19(10):39-46, 56.
34. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005;100(10):2239-2247.
35. Managing the costs of your IBD care. Crohn's & Colitis Foundation of America website. http://www.ccfa.org/assets/pdfs/managing-costs-of-ibd.pdf. Accessed January 21, 2016.
36. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther. 2006;13(6):502-506.
37. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled mainte-nance treatment with infliximab for Crohn’s disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x.
38. Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28(10):1230-1239. doi: 10.1111/j.1365-2036.2008.03839.x.
39. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose esca-lation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26(11-12):1509-1520.
40. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalim-umab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27(7):609-621. doi: 10.2165/11312710-000000000-00000.
41. Bakhshai J, Bleu-Lainé R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ. 2010;13(1):63-69. doi: 10.3111/13696990903543424.
42. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016;111(1):15-23. doi: 10.1038/ajg.2015.207.
43. Van der Valk M, Mangen MJ, van der Have M, et al. P525 evo-lution of IBD-related costs over two years of follow up: increase of anti-TNF ± therapy related costs with a decline of hospitalization costs. European Crohn’s and Colitis Organisation website. https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p525-evolution-of-ibd-related-costs-over-two-years-of-follow-up-increase-of-anti-tnf-x03b1-therapy-related-costs-with-a-decline-of-hospitalization-costs.html. Published 2015. Accessed January 28, 2016.
44. Rubin DT, Mody R, Davis KL, Wang CC. Real-world assess-ment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143-1155. doi: 10.1111/apt.12727.
45. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39(12):1349-1362. doi: 10.1111/apt.12749.
46. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19(7):1528-1533. doi: 10.1097/MIB.0b013e31828132cb.
47. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29(3):247-257. doi: 10.1111/j.1365-2036.2008.03865.x.
48. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53(4):1020-1024.
49. Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8(9):927-935. doi: 10.1016/j.crohns.2014.02.021.
50. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7(1):6-19. doi: 10.1038/mi.2013.73.
51. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674-684. doi: 10.1038/ajg.2011.60.
52. Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF. Loss of treat-ment response to infliximab maintenance therapy in Crohn’s disease: a payor perspective. Value Health. 2008;11(5):820-829. doi: 10.1111/j.1524-4733.2008.00335.x.


PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up